ReviewClinical rheumatology2011
The value of early intervention in RA--a window of opportunity.
Review in Clinical rheumatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2016Pooled it
- Initial Treatment with Biological Therapy in Rheumatoid Arthritis.Journal of clinical medicine · 2023Review
- Physical Exercise and Occupational Therapy at Home to Improve the Quality of Life in Subjects Affected by Rheumatoid Arthritis: A Randomized Controlled Trial.Healthcare (Basel, Switzerland) · 2023Article
- Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy.Rheumatology (Oxford, England) · 2022Article
- Article
- The number of risk factors for persistent disease determines the clinical course of early arthritis.Rheumatology (Oxford, England) · 2021Article
- The tellurium-based immunomodulator, AS101 ameliorates adjuvant-induced arthritis in rats.Clinical and experimental immunology · 2021Article
- A genome-wide association study identifying the SNPs predictive of rapid joint destruction in patients with rheumatoid arthritis.Biomedical reports · 2021Article
- An Advanced Clinician Practitioner in Arthritis Care (ACPAC) Maintains a Positive Patient Experience While Increasing Capacity in Rheumatology Community Care.Journal of multidisciplinary healthcare · 2021Article
- Joint Destruction Is Associated With All Types of Cardiovascular Events in French Rheumatoid Patients: A Real-Life Study With Very Long Follow-Up.Frontiers in medicine · 2020Article
- Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis.Journal of personalized medicine · 2019Review
- Cross-cultural adaptation of the connective tissue disease screening questionnaire and development of a Chinese version in a multi-ethnic Asian population.Clinical rheumatology · 2019Article
- Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2019Review
- An advanced clinician practitioner in arthritis care can improve access to rheumatology care in community-based practice.Journal of multidisciplinary healthcare · 2019Article
- Article
- Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives.RMD open · 2019Review
- Can baseline ultrasound results help to predict failure to achieve DAS28 remission after 1 year of tight control treatment in early RA patients?Arthritis research & therapy · 2018Observational
- Development of Diagnostic Techniques for Early Rheumatoid Arthritis Using Positron Emission Tomography with [Molecular imaging and biology · 2017Article
- Decrease in bone mineral density during three months after diagnosis of early rheumatoid arthritis measured by digital X-ray radiogrammetry predicts radiographic joint damage after one year.Arthritis research & therapy · 2017Article
- Stratified medicine in rheumatoid arthritis-the MATURA programme.Rheumatology (Oxford, England) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is associated with progressive joint destruction, with functional status influenced by both disease activity and radiographic progression. The case for early aggressive treatment of RA is based on large amounts of good data in many countries. Studies with conventional disease-modifying anti-rheumatic drugs in early RA have shown improved outcomes compared with later treatment, especially if an aggressive approach with combinations of drugs is used. Early intervention with tumour necrosis factor (TNF) inhibitors has been shown to improve clinical outcomes, induce remission and prevent radiographic progression. It also improves patients' functional status, health-related quality of life, and reduces fatigue. Patients with RA have reduced productivity, an increased number of lost work days and retire early; enabling patients to work should be at the core of a therapy's cost-effectiveness. Introduction of anti-TNF therapy early in RA has been shown to decrease job loss and reduce the amount of working time missed. Although the drug costs of initial treatment with combination therapy including a TNF inhibitor are high, these may be compensated by the reduction in lost productivity, making such a strategy cost-effective overall. In addition, some patients who respond well to combination therapy may be able to stop the TNF inhibitor. It is important to assess the benefits of any intervention not just to healthcare costs but to society as a whole, and physicians should be advocates for optimal access to effective therapies for their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.